Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10102101 | 0.93 | ITGB3 (0.33) | ITGB3ITGA2BALDH1A1TSHRMAPT | |
| SCHEMBL14679438 | 0.78 | MCHR1 (0.37) | ITGB3ITGA2BALDH1A1CYP3A4TSHR | |
| SCHEMBL16015534 | 0.78 | LMNA (0.36) | CYP3A4TSHRMAPTLMNAKMT2A | |
| SCHEMBL10102104 | 0.74 | ITGB3 (0.36) | ITGB3ITGA2BALDH1A1CYP3A4TSHR | |
| SCHEMBL10107717 | 0.72 | LMNA (0.42) | L3MBTL1CYP3A4TSHRMAPK1MAPT | |
| SCHEMBL10107544 | 0.71 | F2 (0.34) | CYP3A4TSHRMAPTMMP13LMNA | |
| SCHEMBL16015533 | 0.69 | LMNA (0.36) | ALDH1A1CYP3A4TSHRMAPTLMNA | |
| SCHEMBL10107750 | 0.69 | FAAH (0.40) | TSHRMAPTLMNA | |
| SCHEMBL10102173 | 0.69 | MAPT (0.43) | L3MBTL1MAPTLMNAMEN1HSP90AA1 | |
| SCHEMBL10107487 | 0.69 | MAPT (0.39) | L3MBTL1ALDH1A1CYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828988-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8367654-B2 | 8-AZA tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-03 | — | — | US | disclosed |
| WO-2010129055-A1 | 8-AZA TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108569-A1 | 8-AZA Tetracycline Compounds | TET1, TET3, HDAC8 | ITGB3 4561/4885ITGA2B 3823/4885L3MBTL1 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.